Durable 52-Week Visual and Functional Gains Following First-in-human ZM-02 Optogenetic Therapy for Advanced Retinitis Pigmentosa (ARVO 2026) - May 8, 2026 - Abstract #5902; Pres time: May 7, 2026; 02:15 PM - 02:30 PM; Location: Bluebird Ballroom 1B; P1 | "Over 80% of treated subjects experienced meaningful improvements in vision, including better ability to recognize objects, move safely in low light, and even perceive colors. These lasting improvements suggest that ZM-02 may offer a new, long-term hope for people living with advanced RP."
First-in-human • Metastases • P1 data • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
|
|
Wenhui Zhou1; Menghan Zhou1; Mojtaba Shirinzadeh1; Haihan Zhang2; Shiyi Yin2; Jingyun Liu4; Alvin Luk3; David Gao5; Wenbin Wei2; Yin Shen1,4
|